FlandersBio on Twitter

Follow us on Twitter



in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Biocartis Group NV: Biocartis announces publication of 2016 Annual Report


Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of its 2016 annual report. read more

BioBase4SME biedt biogebaseerde start-ups en KMO’s een kostenloze, intensieve business training voor succesvol innoveren aan


Het BioBase4SME project (met co-financiering van het Europese Interreg NWE Programma) biedt jonge start-ups en KMO’s actief in de bio-economie, kostenloos een gespecialiseerde training voor succesvol innoveren aan. Deze training heeft een commerciële waarde van 7000 €. Het intensieve ‘Innovation Biocamp’ dompelt deelnemers een week lang onder in een geheel van opleidingen die hen zullen ondersteunen bij het commercialiseren van hun innovatie en de verdere groei van hun bedrijf. Het Biocamp culmineert in een live pitch voor een panel van investeerders. read more

Belgian PCR interpretation software company UgenTec partners with multiplex molecular diagnostics innovator PathoFinder


Artificially intelligent PCR interpretation solution rolled out in more than ten laboratories spread over Europe and the Middle East read more

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee


Paves the way for submission of a Marketing Authorization Application for ATIR101™ in Europe read more

VIB and DNAlytics team up to develop non-invasive Colorectal Cancer screening test


VIB and DNAlytics are proud to announce their partnership to develop a data-driven, high-performance and non-invasive Colorectal Cancer screening test, the ColonoKit. Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Based on a research program from VIB, KU Leuven and UZ Leuven, with the support of the Fournier Majoie Foundation, DNAlytics will develop the ColonoKit which should make it possible to detect colorectal cancer in an early stage using a simple blood test. read more

BioBase4SME Natural Fibertastic Workshop aims to encourage SMEs to apply for fully funded Bio-Innovation Coupons for fibre application testing


The BioBase4SME project (co-financed by Interreg NWE), offering bio-innovation support for SMEs, herewith proudly announces its Natural Fibertastic Workshop hosted at the Natural Fiber Application Center (NAC, The Netherlands) on April 5th, 2017. read more

MDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence


MDxHealth SA (Euronext: MDXH.BR) today announced that results from a prospective study demonstrate that biomarkers from its ConfirmMDx® for Prostate Cancer test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).1 CRPC is an aggressive form of the disease that doesn't respond to traditional, hormone deprivation therapies. The study findings were presented at the 2017 European Association of Urology (EAU) Annual Congress in London, England. read more

Imec to Honor Samsung’s Dr. Kinam Kim With “Lifetime of Innovation Award”


Imec, the world-leading research and innovation hub in nano-electronics and digital technologies, is granting its Lifetime of Innovation Award to Dr. Kinam Kim, President and CEO of Semiconductor Business at Samsung Electronics. The selection recognizes Dr. Kim’s leadership and strategic vision, as well as his undeniable impact in the semiconductor industries. read more

Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings


Today Galapagos NV (Euronext & NASDAQ: GLPG) published its Annual Report for the financial year 2016. read more

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017


First clinical trial of CAR-T NKR-2 cell therapy completed with encouraging safety profile and unexpected signals of clinical activity at the low doses tested. Strong cash position expected to fund operations until mid-2019. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top